Education
About Us
Working with TipRanks
Follow Us
Ryvu Therapeutics SA (DE:9Y4)
FRANKFURT:9Y4
Total Valuation
Ryvu Therapeutics SA has a market cap or net worth of €145.65M. The enterprise value is €657.21M.
Market Cap€145.65M
Enterprise Value€657.21M
Share Statistics
Ryvu Therapeutics SA has 23,120,148 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,120,148
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ryvu Therapeutics SA’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -45.07%.
Return on Equity (ROE)-0.77
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-45.07%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee237.71K
Profits Per Employee-339.74K
Employee Count328
Asset Turnover0.21
Inventory Turnover16.18
Valuation Ratios
The current PE Ratio of Ryvu Therapeutics SA is ―. Ryvu Therapeutics SA’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value6.19
Price to FCF0.00
Price to Operating Cash Flow-5.18
PEG Ratio―
Income Statement
In the last 12 months, Ryvu Therapeutics SA had revenue of 77.97M and earned -111.44M in profits. Earnings per share was -4.82.
Revenue77.97M
Gross Profit58.39M
Operating Income-122.10M
Pretax Income-111.14M
Net Income-111.44M
EBITDA-96.83M
Earnings Per Share (EPS)-4.82
Cash Flow
In the last 12 months, operating cash flow was -130.43M and capital expenditures -5.86M, giving a free cash flow of -136.28M billion.
Operating Cash Flow-130.43M
Free Cash Flow-136.28M
Free Cash Flow per Share-5.89
Dividends & Yields
Ryvu Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.14
52-Week Price Change-46.73%
50-Day Moving Average6.75
200-Day Moving Average6.82
Relative Strength Index (RSI)42.88
Average Volume (3m)4.00
Important Dates
Ryvu Therapeutics SA upcoming earnings date is Nov 20, 2025, TBA (Confirmed).
Last Earnings DateSep 11, 2025
Next Earnings DateNov 20, 2025
Ex-Dividend Date―
Financial Position
Ryvu Therapeutics SA as a current ratio of 2.52, with Debt / Equity ratio of 62.07%
Current Ratio2.52
Quick Ratio2.51
Debt to Market Cap0.08
Net Debt to EBITDA0.87
Interest Coverage Ratio-32.06
Taxes
In the past 12 months, Ryvu Therapeutics SA has paid 297.00K in taxes.
Income Tax297.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Ryvu Therapeutics SA EV to EBITDA ratio is -8.32, with an EV/FCF ratio of -5.95.
EV to Sales10.33
EV to EBITDA-8.32
EV to Free Cash Flow-5.95
EV to Operating Cash Flow-6.22
Balance Sheet
Ryvu Therapeutics SA has €174.01M in cash and marketable securities with €74.23M in debt, giving a net cash position of €99.78M billion.
Cash & Marketable Securities€174.01M
Total Debt€74.23M
Net Cash€99.78M
Net Cash Per Share€4.32
Tangible Book Value Per Share€5.87
Margins
Gross margin is 74.84%, with operating margin of -156.60%, and net profit margin of -142.92%.
Gross Margin74.84%
Operating Margin-156.60%
Pretax Margin-142.54%
Net Profit Margin-142.92%
EBITDA Margin-124.20%
EBIT Margin-137.66%
Analyst Forecast
The average price target for Ryvu Therapeutics SA is €5.85, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target€5.85
Price Target Upside-7.87% Downside
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―